Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

Neuro-Oncology

Volumn 11, Issue 5, 2009, Pages 550-555

  Quant, Eudocia C ^a,b,c   Norden, Andrew D ^a,b,c   Drappatz, Jan ^a,b,c   Muzikansky, Alona ^a   Doherty, Lisa ^b   LaFrankie, Debra ^b   Ciampa, Abigail ^b   Kesari, Santosh ^a,b,c   Wen, Patrick Y ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bevacizumab; High grade glioma; Malignant glioma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; IRINOTECAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67649092660     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2009-006     Document Type: Article

References (20)

1. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol. 2007;19:598-605.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
3. Cloughesy T, Prados M, Wen PY, et al. A phase II, randomized, noncomparative clinical trial of bevacizumab alone or in combination with irinotecan prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma [abstract]. J Clin Oncol. 2008;26:2010b.
4. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787.
5. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260. (Pubitemid 43739717)
6. Stark-Vance V. Bevacizumab (Avastin® ) and CPT-11 (Camptosar® ) in the treatment of relapsed malignant glioma [abstract]. Neuro-Oncology. 2005;7:369.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259. (Pubitemid 46424067)
8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
10. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res. 2005;27:371-377. (Pubitemid 40734696)
11. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007;7:1537-1560.
12. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008;8:541-553. (Pubitemid 351570416)
13. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
14. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593. (Pubitemid 30636298)
15. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain tumor Group. J Clin Oncol. 1999;17:2762-2771. (Pubitemid 29415233)
16. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624-6628. (Pubitemid 32896475)
17. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to antiangiogenic glioma therapy. Acta Neurochir Suppl. 2003;88:169-177.
18. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306-314. (Pubitemid 30703463)
19. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncology. 2004;6:21-27.
20. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain tumor Consortium study. Neuro-Oncology. 2006;8:189-193. (Pubitemid 46542664)